BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for

Event · Exec change
Person
Peter J. Pitts
Title
Executive Chairman and Chief Strategic Regulatory and Policy Officer
Action
appointed
Predecessor
Professor Jacob Frenkel

Facts are quoted from the filing text and checked against it.

Original reporting
Published Jul 30, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$BCLI
Neutral
medium confidence
Mentioned
$BCLI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BCLINeutralLow
01

Why it matters

This disclosure primarily updates management compensation via a stock option grant, with no direct information on trials, approvals, or financial performance in the provided text.

02

Market read

For BCLI, the actionable takeaway is the CEO option grant terms (exercise price, share count, vesting), which is typically low-impact versus clinical or financial catalysts.

03

What to watch

Traders may want to check whether this 8-K also includes director/officer departures or elections beyond the excerpt, since Item 5.02 can bundle multiple governance changes.

Relevance 6/10Novelty 3/10Timing: filed 2026-07-30 (after market close)

Background

The SEC 8-K Item 5.02 covers departures/elections/appointments and compensatory arrangements for certain officers.

Company-level read

Ticker impact

$BCLINeutralMedium confidence
Context

BCLI filed an 8-K for Item 5.02, granting a nonqualified stock option to CEO Peter Pitts with a $1.00 exercise price and 900,000 shares.

Expected impact

Likely limited, with any reaction driven by optics of compensation rather than new financial guidance.

Evidence & confidence

The text provides option grant mechanics (exercise price, share count, vesting) but no new clinical, revenue, or regulatory catalyst.

Market effects

Minimal; equity-compensation disclosures are common in biotech and do not change sector fundamentals by themselves.

None indicated.

None indicated.

Counterpoint

Option grants can sometimes signal retention concerns or compensation restructuring, but this filing alone does not provide evidence of distress.

Key entities

  • BRAINSTORM CELL THERAPEUTICS INC.

    Company filing the 8-K and granting equity compensation under its 2014 Stock Incentive Plan.

  • Peter Pitts

    CEO listed as the option participant in the stock option grant notice.

Related articles

$BCLIMed

BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND

$BCLIMed

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, November 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegener

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerativ

$ORCLMed

Oracle says OpenAI infrastructure deal is fully funded after final capital raise

Oracle announced its infrastructure deal with OpenAI is fully funded after a $20B capital raise. Shares rose 3.3% in after-hours trading. The company plans to expand data-center capacity, including a 4.5GW project in the US. Oracle confirmed financing is in place, with additional vendor discussions as options. The Abilene campus, where OpenAI’s GPT-6 Astra was trained, is nearly complete.

$SXTPHighAI 9/10

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc.…

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Na